CAJ | 학술논문

目的：观察厄贝沙坦对IgA肾病的疗效及其安全性。方法：将IgA肾病患者62例随机分为治疗组32例和对照组30例。治疗组给予双嘧达莫150mg／d、厄贝沙坦150mg～300mg／d，共12周；对照组单纯给予双嘧达莫150mg／d，共12周；观察两组患者治疗前后收缩压、舒张压、24h尿蛋白定量、血尿素氮、肌酐和血K±等变化。结果：治疗12周后治疗组患者收缩压（ SBP ）、舒张压（ DBP ）、24h尿蛋白定量、血尿素氮（BUN）、肌酐均降低（P＜0．05）；对照组患者用药后收缩压（SBP）、舒张压（DBP）、24h尿蛋白定量、血尿素氮（BUN）、肌酐均无明显降低（P＞0．05）。结论：厄贝沙坦治疗IgA肾病能明显降低血压、减少尿蛋白，改善肾功能，且无明显不良反应。
목적：관찰액패사탄대IgA신병적료효급기안전성。방법：장IgA신병환자62례수궤분위치료조32례화대조조30례。치료조급여쌍밀체막150mg／d、액패사탄150mg～300mg／d，공12주；대조조단순급여쌍밀체막150mg／d，공12주；관찰량조환자치료전후수축압、서장압、24h뇨단백정량、혈뇨소담、기항화혈K±등변화。결과：치료12주후치료조환자수축압（ SBP ）、서장압（ DBP ）、24h뇨단백정량、혈뇨소담（BUN）、기항균강저（P＜0．05）；대조조환자용약후수축압（SBP）、서장압（DBP）、24h뇨단백정량、혈뇨소담（BUN）、기항균무명현강저（P＞0．05）。결론：액패사탄치료IgA신병능명현강저혈압、감소뇨단백，개선신공능，차무명현불량반응。
Objective:To investigate the effect and the safety of irbesartan on IgA nephropathy.Meth-od:Sixty-two cases of IgA nephropathy were randomly divided into treatment group and control group.Pa-tients of treatment group ( n=32) were given 150mg dipyridamole and 150~300mg irbesartan, and the pa-tients of control group ( n=30) were given 150mg dipyridamole per day for 12 weeks.Systolic blood pressure, diastolic blood pressure, proteinuria in 24 hours, blood urea nitrogen, creatinine and potassium were ob-served.Result:Systolic blood pressure, diastolic blood pressure, proteinuria in 24 hours, blood urea nitro-gen and creatinine in treatment group decreased obviously (P<0.05).There was no decrease(P>0.05) in control group after treatment.Conclusion: Irbesartan can obviously reduce blood pressure and proteinuria, improve renal function without severe side-effects in treating IgA nephropathy.